Experimental drug Nilotinib in Parkinson's Disease
Logo Image
"Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!"
Age: 40 to 79 years old
Healthy Volunteers: No
Keywords: parkinson, nilotinib
Type: Drug study, Phase 2
The purpose of this study is to determine if a drug called Nilotinib is safe, if it can be tolerated by patients with PD, and to learn if Nilotinib has the possibility of effectively treating Parkinson's Disease symptoms. Nilotinib has been approved by the Food and Drug Administration (FDA) to treat certain types of cancer (leukemia) but is considered investigational in this study because it has not been approved for treating PD.
In this study, we are comparing two doses (150mg or 300mg) of Nilotinib to placebo (a pill that looks like the study drug but does not have any active medication in it, like a sugar pill).
This study requires

1) Your participation will last approximately 8 to 9 months and will include 13 in person clinic visits. 2) Participants will be randomly assigned to receive daily oral doses of nilotinib or placebo - an inactive pill used in research studies to determine if the active study drug is effective. 3) Several blood samples will be collected throughout the study, along with required lumbar punctures at certain visits (2-3 total).

Who can participate

You may qualify for this study if you:

1) Are between 40 and 79 years of age 2) Have had PD for at least 5 years 3) You have been on a stable regimen of PD medications for at least 30 days prior to the screening visit 4) You are willing to undergo 2-3 lumbar punctures

Benefits and risks of participating
Nilotinib may help to normalize the function of pathways in the brain and reduce alpha-synuclein from collecting, potentially helping to relieve PD symptoms. Additionally, you may be contributing to the growing knowledge about PD.
$100 or $200 per visit (depending on the visit completed)
Study duration and period
8.5 - 9 months
Recruitment period
From Nov. 27, 2017
Olga Kishchenko, Clinical Research Coordinator
Research Topic
  • Parkinson Disease

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:

E-mail Preview